• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Bellicum Pharmaceuticals

edit

Bellicum Pharmaceuticals, Inc. is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum’s novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. Our lead product, BP-GMAX-CD1, is in Phase I clinical trials.

Milestones

edit

• 
  Bellicum Pharmaceuticals added David M. Spencer as CSO.
  Posted 11/4/09 at 5:47pm
• 
  Bellicum Pharmaceuticals added Thomas J. Farrell as President and CEO.
  Posted 11/4/09 at 5:47pm
• 
  Bellicum Pharmaceuticals added Kevin Slawin as Founder, Executive Chairman, CMO. (7/1/04)
  Posted 11/4/09 at 5:47pm
• 
  Bellicum Pharmaceuticals received $5.7M in Unattributed funding. (3/25/11)
  Posted 3/25/11 at 4:17pm via fiercebiotech.com
• 
  Bellicum Pharmaceuticals received $4.5M in Series A funding. (11/4/09)
  Posted 11/4/09 at 5:49pm via bellicum.com
• 
  Bellicum Pharmaceuticals received $1.45M in Grant funding. (10/9/07)
  Posted 11/4/09 at 5:47pm via bellicum.com
• 
  Bellicum Pharmaceuticals received $2.3M in Seed funding. (10/9/07)
  Posted 11/4/09 at 5:47pm via bellicum.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 11/3/11

Sources

1. BELLICUM PHARMACEUTICALS ANNOUNCES $3.75 MILLION IN FINANCING (bellicum.com) [edit]
2. BELLICUM PHARMACEUTICALS ANNOUNCES $3.75 MILLION IN FINANCING (bellicum.com) [edit]
3. BELLICUM PHARMACEUTICALS ANNOUNCES $4.5 MILLION IN NEW FUNDING (bellicum.com) [edit]
4. Bellicum receives $5.7M in funding for CaspaCIDe (fiercebiotech.com) [edit]